Kornimate/medical-research-clean huggingface dataset:
role of adrenomedullin in leukemic endosteal/vascular niches

Conditions: Acute Myeloid Leukemia

Summary: the present study will be divided into 5 phases: 1. collection of bone marrow and peripheral blood (pb) samples from aml patients at diagnosis; 2. measurement of midregional proadrenomedullin (mr-proadm) plasma concentrations with an immunoluminometric assay of newly diagnosed aml patients not affected by concomitant cardiovascular disease or sepsis. 3. analysis of exosomes and microvesicles derived from pb and bone marrow samples of aml patients and culture media collected from aml samples stimulated with adm and/or adm (22-52) 4. study of adrenomedullin system in leukemic stem cells (cd44+/cd38-/cd31+/lin-) in order to define a correlated expression of adm and adm receptors (ramps, pam) with adhesion molecules (cd31, cd38, cd44s, cd44v6), cell cycle regulatory proteins (p21, p27) and genes or molecules involved in the hematopoietic differentiation process (cul5, cd11b, cd11c, cd66, cd14, cd15, pml-rarα) 5. in vitro evaluation of adm activity in the growth, maturation and trans-endothelial migration of blasts and/or fusion of leukemic cells with endothelial cells. to do this, leukemic cells will be alternatively cultured by using in vitro models of endosteal and vascular niches.


Eligibility criteria:
inclusion criteria: 1. patients with new diagnosis of primary or secondary aml. 2. participant is willing and able to give signed written informed consent according to ich/eu/gcp and national local laws. 3. male or female, aged \>18 years. exclusion criteria: 1. patients affected by concomitant cardiovascular disease , such as essential hypertension (any grade), chronic renal failure (creatinine\>1.5 mg/dl), heart failure (any nyha class), and peripheral arterial occlusive diseases, or sepsis. 2. patients affected by hiv, b or c hepatitis.

Keywords: adrenomedullin
anti-tumor necrosis factor therapy in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: assessed using (1) adalimumab(humira) and nsaids (2) use only adalimumab(humira) treatment of ankylosing spondylitis patient safety and efficacy.

in this study, single center, treatment, open, randomized, controlled clinical trial to assess adalimumab(humira) style with nsaids for the treatment of patients with ankylosing spondylitis, a total of 300 are expected to be included in the consent form signed by the subject, will be randomly assigned to treatment groups with a control group of 150 people. subjects to be returned in the first week outpatient follow 0,8,20,44,68,92 accept routine physical examination (weight, blood pressure, etc.), as scale (basdai, basfi, bas-g), fingertip ground tests, lumbar range of motion, chest expansion test, lateral bending test, the occipital bone measurements, physician global assessment (physician global assessment), patient pain scores (vas), as quality of life scale (asqol), sf-36 quality of life scale, complete joint assessment, asas20 response criteria, assessment of laboratory analysis inflammation index (hs-crp, iga, esr), safety index checks (cbc, sgpt, serum creatinine, hbv-dna if hbsag (+), hcv -rna if hcvab. subjects need to return opd week 0, accept anti-hbs, anti-hbc, hbsag, anti-hcv. subjects required to return to the first outpatient follow 0,20,92 weeks, pulmonary function tests. therefore, the subjects in the 92 weeks of the trial, a total need for blood six times, each time for blood about 10 cc. and to assess side effects and adverse events (adverse event, ae), serious adverse events (serious adverse event, sae)

Eligibility criteria:
inclusion criteria: * age ≥18 years old * hla b27 positive * x ray examination * clinical symptoms and physical examination, the following three conditions are subject to at least two: i.lower back pain and morning stiffness symptoms persist more than 3 months ii. lumbar activity is restricted iii. chest expansion is restricted * active disease for four weeks or more (continue two examination basdai\>6, esr\> 28 mm/1 hr and crp\>1 mg/dl) exclusion criteria: * pregnant or breast-feeding women * patients with active infections * highly infectious patients * cancer or precancerous condition of the patient * multiple sclerosis

Keywords: adalimumab nsaids safety efficacy
louisiana state university health care sciences division (lsu hscd) tele-health projects: adult chf patient population

Conditions: Congestive Heart Failure

Summary: the purpose of this research study is to see whether a tele-health intervention can improve health, functioning status, emotional status, quality of life, and patient satisfaction for patients with congestive heart failure (chf) and to examine the cost benefits of this intervention.


Eligibility criteria:
inclusion criteria: * equal to or greater than 18 years old * 1 + past chf diagnosis in lsu database, with history of chf diagnosis extending back for 12 months * lsu primary care or chronic disease clinic patient for equal or greater than 6 months. * on chf medication for equal to or greater than 6 months * have had a past echocardiogram * mental competency to consent and participate (determined by clinical judgment and chart abstraction) * physically able to use in-home equipment (or presence of a household member who can assist the subject in equipment use) * currently-working conventional telephone line at primary residence * grounded electrical power supply at primary residence * anticipation of remaining in the lsu hcsd patient population for the next year * not on home oxygen therapy * no planned surgery within the next six months * living at home (not institutionalized) * no history of major organ transplant * no diagnosis of metastatic or inoperable cancer * not under treatment for cancer * not under treatment for end-stage renal disease or end-stage liver disease * 1 + emergency department visit or inpatient stay in past 12 months exclusion criteria: * are on home oxygen * have a planned surgery within the next 6 months * have a history of major organ transplant * have a diagnosis of metastatic or inoperable cancer * are under treatment for cancer * are under treatment for end-stage renal disease or end-stage liver disease * have hiv/aids * have a cognitive condition, such as alzheimer's or dementia that would make it difficult for you to understand how to use the tele-health device.

Keywords: congestive heart failure systolic chronic disease heart failure
tailored covid-19 testing support plan for francophone african born immigrants

Conditions: COVID19 Testing

Summary: the goal of this clinical trial is to test the effectiveness of a culturally sensitive covid-19 testing intervention designed for francophone (french speaking) african born immigrants (fabi) . the main question this study aims to answer is whether or not a a culturally sensitive covid-19 educational pamphlet added to the home-based test will improve testing rates compared to receiving a standard home-based test alone.

upon consenting, all participants will receive basic covid-19 testing instructions from trained bilingual/bicultural francophone african born immigrant (fabi) community health workers (chw's). next, participants will be randomly assigned to either the control or intervention study arms. in the control condition (n=50) participants will receive a standard covid-19 home-based test kit. in contrast, those assigned to the intervention condition (n=50) will receive the same covid-19 home-based test kit plus a fabi culturally sensitive covid-19 educational pamphlet. lastly, (n=10) participants from each arm will be randomly selected to participate in qualitative interviews to assess their experiences with chws and their test kit.

Eligibility criteria:
inclusion criteria: fabi living in dallas fort worth (dfw) - exclusion criteria: none -
cmc arthritis - neoprene vs. thermoplast short opponens splinting

Conditions: Carpometacarpal Thumb Arthritis

Summary: carpometacarpal thumb arthritis is a disease caused by different factors and attacks mainly woman older than 50 years. the signs and symptoms consist in pain, swelling, joint instability, deformity and loss of motion. some evidence has shown that splinting of the thumb may be of benefit. there are two methods of splinting: the first is standard neoprene wrap-on thumb support (in which the finger is kept in the same position with in a standard neoprene thumb splint). the second is thermoplast short opponens splint (this splint is custom-made and the thumb is use as a template to design the splint). the purpose of this study is to test and evaluate these two protocols of splinting and assess which one helps or works better in patients with thumb arthritis.

osteoarthritis of the thumb carpometacarpal joint is a common condition that affects approximately 16% to 25% of postmenopausal woman and causes pain, swelling, instability, deformity and loss of motion. this condition has been staged in 4 periods according to the degree of severity. mild stages or stages 1 and 2 are usually treated conservatively by stabilization of the joint, which can be aggressively achieved by surgical ligament reconstruction or conservatively with thumb splints. splinting is a typical treatment for osteoarthritis of the thumb with the goals of managing pain, stabilizing the cmc joint, and improving overall thumb function. there are limited studies showing the effectiveness of splinting for this condition indicating they are successful in decreasing pain and improving function in activities of daily living as well as radiographically improving joint stability. what is less clear is, once patients leave the clinic setting, how compliant they are with their splinting regimen. patients with chronic illnesses tend to have compliance issues when it comes to their care. also, there are limited studies comparing different modalities of splinting. a recent study compared custom-made short opponens thermoplastic splint with the metacarpo-phalangeal (mp) joint free to a pre-fabricated short neoprene splint. they found that patients preferred the neoprene splint but both splints provided some degree of pain relief, reduction of subluxation of the mp joint and improvement in function. our purpose is to objectively quantify the various benefits of splinting for patients with thumb arthritis using the dash score and assess if there is a difference between the pre-fabricated neoprene splint and the custom-made short opponens thermoplastic splint with the mp included.

Eligibility criteria:
inclusion criteria: * patients aged 18 or older. * males and females diagnosed using clinical criteria as having cmc thumb arthritis * radiological diagnosis is not necessary exclusion criteria: - patients with previous history of cmc thumb arthritis treated surgically

Keywords: cmc arthritis splint treatment patient satisfaction dash questionnaire
a study of sleep patterns to determine predictive markers due to cardiovascular disease in elderly patients

Conditions: Cardiovascular Diseases

Summary: the purpose of this study is to learn if there are predictive markers of hospitalization or death that can be found from data gathered from a sleep number® bed. this is a prospective observational cohort study that will follow participating subjects in the masonic homes/acacia creek retirement community in union city, california.


Eligibility criteria:
inclusion criteria: * subjects living at masonic homes/acacia creek retirement community who use a sleep number® bed and are cognitively able to consent on their own accord. exclusion criteria: * subjects who do not have a sleep number® bed. * subjects without an internet connection to transmit nightly sleepiq® data.

Keywords: elderly patients sleep patterns
evaluation of parameters collected from routine data for the diagnosis of sepsis and septic shock and their influence on time to diagnosis and patient outcome

Conditions: Sepsis; Septic Shock

Summary: retrospective observational study to develop a machine learning algorithm to evaluate parameters collected from routine data for the diagnosis of sepsis and septic shock and their influence on time to diagnosis and patient outcome.

retrospective routine data from the medical records of the department of anesthesiology and operative intensive care from 01. 01. 2007 to 31. 12. 2021 are analyzed in digital form. the first step is the development of a machine learning algorithm (mla). this mla will be validated and analyzed for his predictive value with regard to early diagnosis of sepsis/septic shock depending on the conceptual value of detection variables (sepsis-3 vs. sirs). further analysis will focus on improvement of accuracy for the mla and the effect of these detection variables on quality of treatment processes and also on economic consequences like cost and revenue. timeline: 1. conception and development of the ml algorithm (6 months) 2. identification and diagnostic validation of sepsis patients (6 months) 3. secondary analyses (36 months)

Eligibility criteria:
inclusion criteria: * age \>= 18 years * icu stay of \> 24 hours exclusion criteria: * none
impact of the covid-19 pandemic on vaccination

Conditions: Covid19

Summary: the vaccination policy is drawn up in france by the french minister of health, who makes public the vaccination schedule after the opinion of the high authority of health. currently according to the 2019 immunization schedule, the dtp vaccine is the only mandatory in the general population with recalls in adults aged 25, 45, 65 and every 10 years. in 2011, the ministry of health estimated that only 50.5% of the general population was up to date against dtp. two vaccines are recommended for person at risk of infection according to the current vaccine schedule: the flu vaccine and the pneumococcal vaccine. in fact, influenza and pneumococcal disease are more frequent and more serious in patients with chronic diseases (diabetes, cardiac insufficiency..) compared to the general population. the vaccination coverage rate of at-risk populations is dramatically below the vaccination coverage targets set by the ministry of health. indeed, there are many barriers to vaccination, medical and para-medical barriers, but also individual barriers. the current covid-19 pandemic has identified people at risk of severe infection and death risk, particularly those with co-morbidities (diabetes, cardiovascular disease, etc.). thus, this pandemic may have contributed to change in patients' perceptions regarding both the risk of infection and the potential interest and benefit of vaccination.


Eligibility criteria:
inclusion criteria: * person at risk of infection according to french 2019 immunization schedule * patients aged above 18 years old exclusion criteria: - patient \< 18 years

Keywords: people over 18 years old vaccines immunization schedule infection
omics4aging: stratification of frailty population

Conditions: Malnutrition; Intellectual Frailty of Aging; Bone Fragility

Summary: the overall objective of the study is to stratify a frailty population based on nutrients profiling (amino acids, vitamins, minerals, fatty acids) and metabolic profiling (low molecular weight metabolites in urine and plasma) at baseline.

this exploratory study will investigate ways to better characterize the frailty phenotype by a combination of i) geriatric assessment (here only: frailty criteria according to fried), ii) clinical surrogate markers (including those of inflammation), iii) body composition, iv) nutritional profiling, v) metabolite profiling using a metabolomics approaches.

Eligibility criteria:
inclusion criteria: unless otherwise specified, subjects who fulfill all of the following will be included: 1. caucasian 2. male or female between the ages of 65 and 79 years old 3. three or more fried frailty criteria (as diagnosed by investigator) 4. informed consent obtained exclusion criteria: any of the following criteria would render a subject ineligible for inclusion: 1. dementia (previously diagnosed by general practitioner) 2. hb1c (glycate haemoglobin) \>7.5% (\>58 mmol/mol). 3. end stage disease (1 year after last chemotherapy treatment for cancer) 4. drug abuse (alcohol - assessed by investigator) 5. medications: no antibiotic treatment (for at least 4 weeks), immune suppressants, and or chronic use of corticosteroids 6. currently participating or having participated in another clinical or nutritional intervention trial during the last 3 month 7. chronic active inflammatory disease (e.g. rheumatoid arthritis, vasculitis, lupus erythematosus and crohn's disease) 8. chronic active hepatitis 9. kidney failure in dialysis treatment 10. any other condition that in the judgment of the lead investigator would not allow the subject to complete the study protocol
comparison of efficacy of metoclopramide , promethazine and prochloroperazine in the treatment of vertigo.

Conditions: Peripheral Vertigo

Summary: background: vertigo as acute symptom seem to be one of most common presentation in ed, can be treated in ed with multiple medication . objective: this study aimed to compare the therapeutic efficacy of metoclopramide, promethazine and prochloroperazine in patients presenting with signs and symptoms suggestive of acute peripheral vertigo to the ed . methods: a 3-arm multi-center, randomized, triple-blind, controlled study comparing three treatments for acute vertigo in three medical centers : alnahdha hospital oman , sohar hospital oman and afh hospital oman. oman from february 2022 to august 2024.

* background vertigo is one of most ed visit symptoms, it can be due to central or peripheral cause. the most frequent three reasons for vertigo are acute peripheral vestibulopathy (vestibular neuritis, labyrinthitis), meniere's disease, and benign paroxysmal positional vertigo (bppv). usually ed doctors started with epley maneuver for relief of symptoms and then started with medication. * objective: this study aimed to compare the therapeutic efficacy of metoclopramide, promethazine and prochloroperazine in patients presenting with signs and symptoms suggestive of acute peripheral vertigo to the ed . • research methods: this will be done by assessing the best medication can be used to treat peripheral vertigo with least side effect through randomized triple blinded analysis will use 3 medications. all medications will be saved in similar syringe with white paper cover and labeled as a,b, c .the treating em doctor will prescribe medication as anti-vertigo then one of covered medication will be randomly taken among 3 medication groups. target population will be all patient in age group (18-60) years visiting the emergency department at al nahdha hospital, afh and sohar hospital who complain of peripheral vertigo after assessment and excluding central cause. ethical approval will be applied for through the omsb (ministry of health ethical committee)

Eligibility criteria:
inclusion criteria: * □ acute peripheral vertigo with nausea or vomiting (vas, visual analog scale \>5) during their emergency department episode of care for which the attending physician recommending antiemetic, onset with in 3 days . * age( 18- 60). exclusion criteria: * • age \>60. * any organic brain disease (clear central cause; "malignancy with brain metastasis".) * history of epilepsy * pregnancy. * dementia, parkinson's disease * abnormal vital signs * any known drug allergy to the study drugs * undergoing chemotherapy or radiotherapy * mechanical bowel obstruction or perforation, gastrointestinal bleeding * inability to understand study explanation or outcome measures (any reason) * patients who refused to participate study.

Keywords: ed vertigo metoclopramide promethazine prochlorperazine
implementing genomics in practice (ignite): cyp2d6 genotype-guided pain management in patients undergoing arthroplasty surgery

Conditions: Pain, Postoperative

Summary: this will be a randomized, open-labeled pilot pragmatic clinical trial. patients undergoing arthroplasty surgery will be recruited from the university of florida (uf) health gainesville and the villages orthopedic clinics for cyp2d6 pharmacogenetic testing to manage post-surgical pain. patients will be randomized 2:1 to either usual care or genotype-guided care. the aims of the study were to: 1) test the feasibility of a genotype-guided opioid prescribing approach for patients undergoing an outpatient surgical procedure, a group at high risk for persistent opioid use; and 2) evaluate the effect of genotype-guided post-surgical pain management on pain control and opioid prescribing.

this study was a randomized, open-label, type 2 hybrid implementation effectiveness trial conducted to test the hypothesis that cyp2d6 genotype-guided management of post-surgical pain 1) was feasible, and 2) reduced the use of codeine, tramadol, hydrocodone, and oxycodone in poor metabolizers (pms), intermediate metabolizers (ims), and ultrarapid metabolizers (ums). in addition to the reduced use of opioids listed above, we aimed to see if participants had improved post-operative pain control in pms/ims and reduced drug enforcement administration (dea) schedule ii (c-ii) opioids in normal metabolizers (nms). patients scheduled to undergo arthroplasty surgery were recruited from the uf health gainesville and the villages orthopedic clinics. patients were randomized 2:1 to a genotype-guided versus usual care approach. for patients with cyp2d6 pm, im or um phenotype based on genotype or drug interactions, a recommendation to avoid hydrocodone, tramadol, codeine, and oxycodone were made. in nms, tramadol was recommended, given evidence of its lower potential addiction risk than c-ii opioids. patient-reported outcomes measurement information system (promis) measures were administered at baseline (within 30 days of surgery) and 2 weeks ± 4 days post-surgery for patients in each arm. pain scores and assessments of physical functioning, emotional functioning, and mobility from the promis measures and utilization of pain medications during the 2-week period following surgery were also compared between groups.

Eligibility criteria:
inclusion criteria: * scheduled to undergo total joint arthroplasty at area hospital * primary unilateral total hip or knee arthroplasty scheduled within approximately 6 months of the initial evaluation clinic visit exclusion criteria: * patients scheduled to undergo a revision or bilateral procedure * receiving chronic opioid therapy, defined as the use of opioids on most days for \> 3 month * allergy to opioids

Keywords: arthroplasty surgery genotype-guided pain management